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Abstract
c-herpesviruses (cHVs) have developed an interaction with their hosts wherein they establish a life-long persistent infection
and are associated with the onset of various malignancies. One critical virulence factor involved in the persistency of murine
c-herpesvirus 68 (cHV68) is the viral homolog of the Bcl-2 protein (vBcl-2), which has been implicated to counteract both
host apoptotic responses and autophagy pathway. However, the relative significance of the two activities of vBcl-2 in viral
persistent infection has yet to be elucidated. Here, by characterizing a series of loss-of-function mutants of vBcl-2, we have
distinguished the vBcl-2-mediated antagonism of autophagy from the vBcl-2-mediated inhibition of apoptosis in vitro and
in vivo. A mutant cHV68 virus lacking the anti-autophagic activity of vBcl-2 demonstrates an impaired ability to maintain
chronic infections in mice, whereas a mutant virus lacking the anti-apoptotic activity of vBcl-2 establishes chronic infections
as efficiently as the wild-type virus but displays a compromised ability for ex vivo reactivation. Thus, the vBcl-2-mediated
antagonism of host autophagy constitutes a novel mechanism by which cHVs confer persistent infections, further
underscoring the importance of autophagy as a critical host determinant in the in vivo latency of c-herpesviruses.
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Introduction
Apoptosis and autophagy, characterized by distinctive morpho-
logical and biochemical changes, are tightly regulated processes
essential for homeostasis, development, and human diseases [1,2].
Once triggered by internal inducers, such as DNA damage and
viral replication, or by external stimuli, such as the engagement of
the TNF receptor, apoptosis proceeds through a cascade of
programmed internal proteolytic digestion, resulting in the
collapse of cellular infrastructure, mitochondrial potential, geno-
mic fidelity, and cell membrane integrity (for review see [1,3]).
Therefore, apoptosis represents an important effector of host
immunity by eliminating virally-infected cells whose survival might
otherwise prove harmful to the host [3]. In contrast to the self-
destructing apoptotic program, cellular autophagy (Greek for ‘self-
eating’) allows cells to engulf cytoplasmic materials, including long-
lived proteins or aberrant organelles, into specialized double
membrane-bound vesicles and deliver them to lysosomes for
degradation and turnover (for review see [4,5]). Although
originally characterized as a cellular response to nutrient
deprivation, autophagy has been increasingly recognized essential
for protecting cells against pathogens [6]. Neuronal overexpres-
sion of the autophagy protein Beclin1 confers resistance to Sindbis
virus infections [7]. Similarly, depletion of beclin1 in plants
aggravates the tobacco mosaic virus-induced hypersensitive
response (HR) [8]. In addition to digesting cellular components,
autophagy has been indicated to sequester virions and bacterial
components for degradation [9,10]. Thus, autophagy constitutes,
in addition to apoptosis, an important host antiviral response [10].
However, the relative contributions and coordination of these two
important pathways during viral infection remain largely un-
known.
Yet as distinct as they are, the apoptotic and autophagic
machinery converge at a number of points. One direct crosstalk
between these two pathways is mediated in part by the functional
and physical interaction of Beclin1, an essential autophagy
activator, with Bcl-2, a prototype apoptosis inhibitor [11,12].
Cellular Bcl-2 was originally discovered as an oncogenic protein in
B-cell lymphomas, since then a number of proteins belonging to
the Bcl-2 family have been identified, each possessing the signature
of Bcl-2 homology domain (BH). The Bcl-2 family consists of both
anti-apoptotic (e.g., Bcl-2, Bcl-XL, and Bcl-w) and pro-apoptotic
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forming homo- or hetero-dimers to regulate the cell’s commitment
to apoptosis [13]. A major mechanism by which the anti-apoptotic
Bcl-2 proteins block apoptosis involves an extended hydrophobic
groove on the surface of the proteins that serves as a binding-
pocket for the a-helical BH3-domain of the pro-apoptotic Bcl-2
family proteins [14,15]. Aside from its ability to interact with and
inhibit pro-apoptotic family members like Bax and BH3-only
proteins, the hydrophobic pocket of Bcl-2 also binds Beclin1 (the
mammalian ortholog of yeast Atg6), which is part of a class III PI3
kinase complex required for the initiation of autophagosome
membrane [16,17]. In fact, the anti-autophagic action of Bcl-2
closely mirrors its capacity to bind and inhibit Beclin1 [12].
Intriguingly, structural analysis of Beclin1 revealed that it possesses
a putative a-helical BH3 domain, which allows Beclin1 to dock
into the hydrophobic pocket of Bcl-2. As such, Beclin1 is recently
considered as a novel BH3-only protein [18,19]. Although it
remains unknown how Bcl-2 discriminates among its targets, the
dual roles of Bcl-2 in apoptosis and autophagy suggest that a
coordinated regulation may exist for Bcl-2 to conduct these two
activities [20].
Given the important role of Bcl-2 in cell survival, many viruses
have evolved to encode structural and functional orthologs of Bcl-2
(vBcl-2s) to prevent the premature death of the infected cells from
sustained viral replication and associated diseases [21,22]. All
sequenced c herpesviruses (cHV) encode a homolog of Bcl-2,
including Epstein-Barr virus (EBV), Kaposi’s sarcoma-associated
herpesvirus (KSHV), herpesvirus saimiri (HVS), and the murine c
herpesvirus 68 (cHV68) [22,23,24]. The vBcl-2 of cHV68 (also
referred to as M11) has been implicated in preventing Bax toxicity
in yeast and blocking apoptosis in cultured cells when induced by
diverse apoptotic stimuli [25,26]. However, cHV68 vBcl-2
appears to be dispensable for acute infection in vivo and lytic
replication in vitro, instead it is proved to be essential for efficient
viral persistent replication as well as reactivation from latency,
characteristic of all cHVs [25,27]. Analysis of the three-
dimensional structure reveals that vBcl-2 of cHV68 has limited
sequence similarity to Bcl-2 but virtually adopts a fold similar to
that of Bcl-2 [25,28]. The seven-helix bundle (a1-7) of vBcl-2
forms a globular structure, where helices 2, 3, 4, and 5 define an
extended hydrophobic surface cleft allowing vBcl-2 to associate
with BH3 domains, especially those of Bak and Bax [25,28].
Mutations within the BH3-binding groove abolished the ability of
cHV68 vBcl-2 to interact with Bax and Bak, block apoptosis, and
abrogate vBcl-2 function in persistent replication and reactivation
from latency in vivo [25]. Thus, it is generally believed that vBcl-2
functions in vivo predominantly by binding and inhibiting pro-
apoptotic Bcl-2 family proteins [25]. Yet, recent evidence favors a
central role for vBcl-2s of cHV in blocking autophagy by directly
interacting with Beclin1 via the BH3-binding groove of vBcl-2
[12,19,29]. Furthermore, the binding of purified vBcl-2 protein to
the Beclin1-derived peptide appears to be the tightest when
compared to peptides from the pro-apoptotic proteins, including
BAX, BAK, BIM, PUMA, BID, and Noxa [28]. Unlike its cellular
counterpart, this vBcl-2-Beclin1 complex can not be easily
displaced by other BH3-only molecules, such as Bid or Bim
[15,28]. Accordingly, vBcl-2 exhibits an enhanced capacity for
autophagy inhibition than cellular Bcl-2 [28,30]. These findings
raise the possibility that evasion of autophagy might also account
for the biological effects of vBcl-2 in viral lifecycle and/or
pathology. Nonetheless, due to the engagement of the hydropho-
bic surface groove of vBcl-2 by both the pro-autophagic BH3
domain of Beclin1 and the pro-apoptotic BH3 domain [28],
mutations of vBcl-2 identified so far that disrupt Beclin1 binding
and inhibition of autophagy also abolish its capacity to interact
with BH3 peptides and inhibit apoptosis, adding to the complexity
of genetically dissecting the in vivo role of vBcl-2-mediated
autophagy inhibition and the vBcl-2-mediated antagonism of
apoptosis in cHV68 infection.
In this study, we used loss of function mutagenesis to determine
the role of vBcl-2-mediated anti-autophagy versus vBcl-2-mediat-
ed anti-apoptosis in the context of cHV68 infection. We found
that a Beclin1-binding-deficient vBcl-2 mutant virus, which is
impaired in autophagy inhibition but retains intact anti-apoptotic
activity, was compromised in the maintenance of latency, though
the initial viral establishment of latency was unaffected. In
contrast, anti-apoptosis-defective vBcl-2 mutant virus infection
was associated with a normal latent load but was largely impaired
in efficient ex vivo reactivation from latency. Our findings thus
demonstrate an as yet undefined function of autophagy in
controlling viral infections. Unlike what was previously thought
that anti-apoptosis features prominently the functions of vBcl-2 in
vivo, our study reveals that an evasion of autophagy-mediated host
innate immunity serves as a key aspect of cHV68 replication and
pathogenesis.
Results
Minimal Region of vBcl-2 Required for Beclin1 Interaction
in Yeast
Beclin1 was originally identified as an interactor of Bcl-2 by a
yeast two-hybrid screen [7]. The a-helical structure of the N-
terminal region of Beclin1 (residues 88–150) mimics the BH3
domain of pro-apoptotic Bcl-2 family members, allowing it to
associate with the hydrophobic BH3-binding groove on the surface
of vBcl-2 [19,28]. However, the Beclin1 peptide (KD 40 nM) binds
to vBcl-2 with a much higher affinity than is observed for the Bak
(KD 76 nM) and Bax peptides (KD 690 nM) [28], raising the
possibility that Beclin1 may not necessarily share binding sites with
the pro-apoptotic Bcl-2 family members for the hydrophobic
groove of vBcl-2. To dissect the specific interacting domain of
vBcl-2 for Beclin1 binding, we created a series of N- and C-
terminal deletion mutations of vBcl-2 (Figure 1), and tested for
Author Summary
Autophagy (‘self-eating’, lysosome-dependent degradation
and recycling of the intracellular components in response
to stress) and apoptosis (‘self-killing’, cells commit suicide
in response to stress) are important host defense
mechanisms against viral infections. c-herpesvirus 68
(cHV68) encodes a Bcl-2 family protein, vBcl-2, that
effectively antagonizes both autophagy and apoptosis
and is required for chronic viral infection and pathogen-
esis. However, the relative contributions of the vBcl-2-
mediated evasion of autophagy and apoptosis to cHV68
persistent infection remain largely unknown. Here, we
characterized a series of vBcl-2 mutants to genetically and
functionally distinguish these closely related activities of
vBcl-2 in vitro and in vivo. We have found that the
inhibition of autophagy by vBcl-2 is important for
maintaining latent infections, while the anti-apoptotic
activity of vBcl-2 is largely involved in efficient viral
reactivation from latency. Our findings thus reveal a novel
paradigm for the vBcl-2-mediated evasion of autophagy
and apoptosis during chronic viral infection, identifying a
vital role for autophagy in controlling cHV68 latent
infection.
Autophagy in Persistent cHV68 Infection
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150) of Beclin1 in the GAL4-based yeast two-hybrid assay [31].
Wild-type (WT) vBcl-2 readily interacted with Beclin1 BH3-like
domain in the yeast two-hybrid assay. In contrast, a vBcl-2 mutant
with a triple alanine substitution at the conserved residues of
Ser85, Gly86, and Arg87 (hereafter termed as vBcl-2 AAA) within
the BH3 binding groove that has been shown to abrogate BH3
peptide binding of vBcl-2, lost the ability to interact with Beclin1
(Figure 1). This was consistent with previous observations
demonstrating that the hydrophobic groove of vBcl-2 is important
for this function [25]. When screening our truncation mutants, we
found that the C-terminal truncations of vBcl-2 up to a7 helix
showed little to no effect on Beclin1 binding; yet a further
truncation up to helix a6 (e.g. vBcl-2 Da6/a7/TM mutant)
severely impaired Beclin1 interaction in yeast (Figure 1), suggest-
ing that the C-terminal boundary of vBcl-2 for Beclin1-binding lies
within the a6 helix because no deletions from this end was
tolerated. Of particular interest, a deletion of the BH2 domain
only, which by analogy to the equivalent domain in Bcl-2 and Bcl-
xL has been shown to abolish binding and inhibition of Bax
[32,33], did not prevent vBcl-2 from binding Beclin1 in yeast
(Figure 1). This data suggests that the BH2 region of vBcl-2 is
dispensable for Beclin1 interaction. In contrast to the C-terminal
moiety, removal of a small segment of the a1 helix at the N-
terminus abrogated the ability of vBcl-2 to interact with Beclin1
(Figure 1). In fact, any segment truncation from the N-terminus of
vBcl-2 resulted in the complete loss of Beclin1 binding (Figure 1).
Thus, our results indicate that the minimal region required for
Beclin1 interaction in yeast involves a helices 1-6 of vBcl-2.
Although the N-terminal a1 helix is not part of the core
hydrophobic a helices within the BH3-binding groove, it does
appear to be critical for mediating Beclin1 interaction in yeast.
vBcl-2 a1 Helix, but not the BH2 Domain, is Required for
Beclin1 Interaction in Mammalian Cells
We next confirmed our yeast two-hybrid results in mammalian
cells. 293T cells were transfected with the WT or mutant forms of
vBcl-2 and/or V5-tagged Beclin1, followed by co-immunoprecip-
itation (co-IP) assays. Consistent with the yeast two-hybrid binding
data, deletion of the N-terminal a1 helix of vBcl-2 abolished
Beclin1 binding, as also seen with the AAA mutant of vBcl-2
(Figure 2A). The loss of binding activity was not due to defects in
protein expressions, since both the Da1 and AAA vBcl-2 mutants
were expressed at equivalent levels to WT in transfected cells
(Figure 2A). Yet, deletion of the a7 or BH2, one of the central
components of the vBcl-2 hydrophobic cleft, had no significant
effect on the interaction between vBcl-2 and Beclin1, as was seen
with the deletion mutation of the C-terminal hydrophobic ‘tail’
(DTM) (Figure 2A). Similar results were also observed with
endogenous Beclin1 in 293T cells, in that removal of the a1 helix
but not the BH2 domain abolished endogenous Beclin1 binding
(Figure 2B). These data thus indicate that while the BH2 region is
structurally important for assembling the hydrophobic core on the
surface of vBcl-2, it is dispensable for vBcl-2-Beclin1 interaction,
whereas the N-terminal a1 helix of vBcl-2 serves as a Beclin1-
interacting domain (Figure 2B). These data are consistent with
those collected from the yeast two-hybrid assay.
Although the N-terminal a1 helix deletion has been previously
shown not affecting the overall folding of Bcl-2 family proteins
[28,34], it remains possible that the inability of the vBcl-2 Da1
constructs to bind Beclin1 could reflect the loss of proper folding of
the protein. To clarify this, we tested whether the mutants of vBcl-
2 retain the ability to associate with other BH3-domain-containing
molecules. Bak has been previously shown to have the highest
affinity to vBcl-2 in vitro among the pro-apoptotic Bcl-2 proteins
Figure 1. Schematic Representation of the Wild Type (WT) and Mutant vBcl-2 Constructs Interacting with Beclin1 in the Yeast-two-
hybrid System. The 171-amino acid sequence of vBcl-2 is indicated at the top with the a-helical structures numbered according to previous
publication [25]. Colored boxes denote the BH 1–4 domains in vBcl-2. ‘‘+’’ : positive interaction, ‘‘2’’ : no interaction. L: linker region; TM:
transmembrane domain; Triple arrows denote the alanine substitutions at Ser85-Gly86-Arg87 within the BH1 domain of vBcl-2.
doi:10.1371/journal.ppat.1000609.g001
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bacteria purified GST-fused Bak protein that was incubated with
the cell lysates of 293T cells transfected with the HA-tagged WT
or mutant forms of vBcl-2 (Figure 2C). The TM domain of Bak
was removed (referred to as GST-BakDTM) to increase its
solubility in E. coli. In agreement with previous studies [25,28], we
observed that Bak was able to associate with the WT and DTM
mutant of vBcl-2, but not with the vBcl-2 AAA mutant (Figure 2C).
No interaction was detected between the vBcl-2 and purified GST
alone, indicating that the vBcl-2-Bak interaction was specific
(Figure 2C). Notably, we found that the Da1 mutant that lacks
Beclin1-binding retained its ability to interact with Bak, whereas
the DBH2 mutant that was able to bind to Beclin1 failed to
interact with Bak (Figure 2C). Thus, the loss-of-function
phenotype of the vBcl-2 mutants for Beclin1 or Bak binding,
particularly that of Da1 and DBH2, is less likely due to misfolding
of the mutant vBcl-2 protein, rather, it implies that the
mechanisms of vBcl-2 for binding with Beclin1 and Bak involve
distinct contact sites within the hydrophobic groove of vBcl-2.
vBcl-2 a1 Helix, but not the BH2 domain, is Required for
the Inhibition of Beclin1-mediated Autophagy
The interaction of Bcl-2 with Beclin1 largely correlates to its
anti-autophagic activity [15]. We then assessed the effects of the
vBcl-2 mutants binding to Beclin1, in particular that of Da1 and
DBH2 mutants, on Beclin1-dependent autophagy. NIH3T3 cells
stably expressing empty vector (NIH3T3.Vector), WT vBcl-2
(NIH3T3.WT), or the mutant forms of vBcl-2, including the Da1,
AAA, Da7, DBH2 and DTM mutants, were generated. To
measure autophagy levels, we initially used the fluorescent
autophagosome marker GFP-LC3 (a mammalian homologue of
the yeast Atg8), which redistributes from a diffused cytosolic/
nuclear staining to a punctate pattern in the cytoplasm upon
autophagy stimulation [35]. We found that, consistent with their
ability to co-IP Beclin1, the vBcl-2 DBH2, Da7, and DTM
mutants suppressed autophagy in these cells as effectively as WT
did under nutrient depletion and rapamycin treatment, the
established inducers of autophagy (Figure 3A and 3B). In contrast,
the Da1 mutant and AAA mutant of vBcl-2, which were unable to
interact with Beclin1, failed to inhibit both starvation- and
rapamycin-induced autophagy in the cells (Figure 3A and 3B).
In accord, a significantly reduced number of autophagosomes per
cell profile was observed in cells expressing WT and the DBH2
mutants, but not the Da1 and AAA vBcl-2 mutants (Figure S1A).
Immunoblotting was then performed with an antibody against
LC3 to further measure autophagy in vBcl-2-expressing cells.
During autophagosome formation, cytosolic LC3 (LC3-I) under-
goes a covalent conjugation to phosphatidylethanolamine (PE) to
yield a lipidated form of LC3, LC3-II, which displays higher
electrophoretic mobility [36]. Consistent with the results of the
GFP-LC3 puncta assay (Figure 3A and 3B), the conversion of LC3
from LC3-I to LC3-II was much reduced in WT and DBH2-
expressing cells compared to that in Da1- and AAA-expressing
cells under normal and rapamycin treatment conditions
Figure 2. vBcl-2 Interaction with Beclin1. (A) Co-immunoprecipitation (Co-IP) of Beclin1 with WT or mutant vBcl-2. 293T cells were transiently
transfected with the indicated constructs, followed by immunoprecipitation of HA-tagged vBcl-2 and immunoblotting of V5-tagged Beclin1. (B) Co-IP
of WT or mutant vBcl-2 with endogenous Beclin1. 293T cells were transfected with the indicated vBcl-2 constructs, followed by immunoprecipitation
of HA-tagged vBcl-2 and immunoblotting of endogenous Beclin1. 1% whole-cell lysates (WCLs) was used as the input. (C) vBcl-2 interaction with Bak
protein. 293T cells were transfected with WT and mutant forms of vBcl-2 as indicated. At 48 h posttransfection, WCLs were mixed either with GST-
BakDTM fusion protein (left panel) or with GST alone (right panel) for an in vitro GST pull-down (GST PD) assays. GST fusion proteins used for the
pulldown assay are indicated (bottom panel). 1% WCL was used as the input. Data are representative of at least three experiments yielding similar
results.
doi:10.1371/journal.ppat.1000609.g002
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vBcl-2 mutant proteins in autophagy inhibition were not due to
their differing protein expression since all tested mutants were
expressed at levels equivalent to WT vBcl-2 in stably transfected
cells (Figure S1B). Furthermore, all of the vBcl-2 mutants exhibited
punctate cytoplasmic staining in the cells, similarly to the WT,
except that the DTM mutant of vBcl-2 showed modest nuclear
staining (Figure S1C). By analogy to the role of the equivalent
region in Bcl-2 relatives, this hydrophobic ‘tail’ probably serves as
a membrane anchor sequence in vBcl-2. While the C-terminal
hydrophobic tail is not required for the function of vBcl-2, it may
contribute to vBcl-2 by ensuring the proper subcellular localization
of the protein. These data collectively demonstrate that the BH2
domain of the hydrophobic groove of vBcl-2 is not essential for
suppressing Beclin1-mediated autophagy and its elimination does
not affect Beclin1 binding, whereas the elimination of a1 helix
leads to the loss of both Beclin1 binding and autophagy
suppressing activity, reflecting a striking correlation between the
ability of vBcl-2 to bind Beclin1 and its protection from Beclin1-
mediated autophagy.
To further address whether vBcl-2 inhibits Beclin1-mediated
autophagy in virally infected cells, we generated recombinant
cHV68 viruses that express HA-tagged WT (referred to as HA-WT)
or mutant forms of vBcl-2 including AAA, Da1a n dDBH2 mutants
(referredtoasHA-AAA,HA-Da1andHA-DBH2,respectively)from
its normal context in the viral genome, using the bacterial artificial
chromosome (BAC) system (for detail please see Material and
Methods). The genomic integrities of all recombinants were
confirmed by restriction enzyme mapping and Southern blot
analyses (Figure S1D). The vBcl-2 protein with the predicted
molecular weight of 18 kDa was detected by immunoblotting using
an anti-HA antibody with all of the recombinant cHV68 viruses in
lytically infected 3T3 fibroblast cells (Figure S2A). Furthermore, the
genetic manipulation of vBcl-2 did not affect expression of the
neighboring v-cyclin (ORF72) in the recombinant viruses (Figure
S2B). NIH3T3 cells were then infected with WT cHV68 or the
recombinant cHV68 virus expressing HA-tagged WT vBcl-2 or its
mutant derivatives. We found that cells infected with the
recombinant cHV68 expressing HA-tagged WT vBcl-2 exhibited
comparable levels of autophagy to those of WT cHV68-infected
Figure 3. Anti-autophagic Activity of the vBcl-2 Mutant Proteins. (A) NIH3T3 cells stably expressing the WT and mutant forms of vBcl-2 were
transfected with GFP-LC3. At 18 h posttransfection, cells were incubated under normal or starvation conditions for 4 h. Autophagy was quantified as
mean6SEM of the combined results from three independent experiments. **, P,0.0001. (B) NIH3T3 cells expressing the WT or mutant forms of vBcl-2
as indicated were transfected with GFP-LC3 and treated with 2 mM rapamycin for 6 h. GFP-LC3 was detected using an inverted fluorescence
microscope (top). Autophagy was quantified as mean6SEM of the combined results from three independent experiments. Scale bar, 5 mm; **,
P,0.01. (C) NIH3T3 cells stably expressing the WT or mutant forms of vBcl-2, as indicated, were treated with 2 mM rapamycin. LC3-I and LC3-II levels
were then determined by immunoblotting with an antibody against LC3 (top). Densitometric quantification of the LC3-II/LC3-I ratios under normal
and rapamycin treatment conditions is shown at the bottom. Similar results were obtained from three independent experiments.
doi:10.1371/journal.ppat.1000609.g003
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(Figure 4). Notably, WT cHV68-infected cells exhibited levels of
autophagy indistinguishable from those of mock-infected cells
(Figure 4). In contrast, 3T3 cells infected with the Beclin1-binding-
deficient vBcl-2 mutant viruses (cHV68 vBcl-2Da1a n dcHV68
vBcl-2AAA) showed significantly higher levels of autophagosome
accumulation than those infected with the WT and DBH2 mutant
viruses (Figure 4). These data indicate that cHV68 infection can
trigger cellular autophagy, which is antagonized by vBcl-2 through
Beclin1 inhibition. Taken together, vBcl-2 efficiently inhibits
Beclin1-mediated autophagy in transfected and virally infected cells,
and that this activity requires the a1 helix of vBcl-2, whereas the
BH2 domain isdispensable for the anti-autophagic activityof vBcl-2.
The BH2 Region, but not the a1 Helix, Is Required for
vBcl-2 Anti-apoptotic Function
Given the pivotal role of vBcl-2 in apoptosis inhibition, it is
important to know if the regions of vBcl-2, which is required for
binding and inhibiting Beclin1, are equally or differentially required
forblocking apoptosis. To this end, we compared the abilities of WT
orthevBcl-2mutantstoconferapoptosisresistance.Upontreatment
withTNFa and cycloheximide(CHX) for12 h, NIH3T3cellsstably
expressing WT, DTM, or the Beclin1-binding deficient Da1 vBcl-2
mutant survived significantly better than those expressing the empty
vector, DBH2, or AAA vBcl-2 mutant (Figure 5A). Further
quantification of the apoptotic cells via TUNEL staining revealed
that the removal of the BH2 domain resulted in the failure of vBcl-2
in inhibiting apoptosis and the accumulation of apoptotic cells
(Figure 5B). In contrast, deleting the a1 helix or the TM region did
not affect the ability of vBcl-2 in suppressing apoptosis (Figure 5B).
Equivalent results were obtained when we used propidium iodide
(PI) staining to determine the accumulation of sub-G1 cells, which
are considered to be apoptotic, via flow cytometry (Figure S3).
Finally, the robust activation of caspase-3, an early event in
apoptosis, was detected in cells stably expressing the vBcl-2 DBH2
and AAA mutants, whereas the expression of WT or the vBcl-2 Da1
Figure 4. The Beclin1-binding a1 Helix of vBcl-2 is Required for Inhibition of Autophagy during cHV68 Infection. (top) Representative
confocal images of GFP-LC3 and HA-tagged vBcl-2 (WT and mutants) in NIH3T3 cells infected with the indicated viruses (MOI=5). Nuclei were
counterstained with 49,69-diamidino-2-phenylindole (DAPI). Scale bar, 5 mm. (bottom) Quantification of the percentage of virally infected cells with
GFP-LC3 punctate staining. Results shown represent mean6SEM of combined results from three independent experiments (200 cells per
experimental condition). *, P,0.01 versus HA-WT; **, P,0.001 versus HA-WT.
doi:10.1371/journal.ppat.1000609.g004
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CHX-(Figure 5C).Thisfurthersupports the notionthat the deletion
of the BH2 domain but not the a1 region seriously attenuates the
ability of vBcl-2 to suppress caspase-dependent apoptosis. Taken
alongside the autophagy analysis data, these results clearly
demonstrate that the vBcl-2-mediated inhibition of apoptosis differs
in important respects with its anti-autophagic activity. As summa-
rized in Table 1, the deletion of the a1 helix in vBcl-2 that prevents
Beclin1 binding and autophagy inhibition generally has little effects
on vBcl-2’ anti-apoptotic activity. In contrast, the removal of the
BH2 region of vBcl-2 that abolishes vBcl-2’s ability to block host-cell
apoptosis has minimal effect on vBcl-2-mediated anti-autophagy.
Thus, vBcl-2-mediated antagonism of autophagy can be structurally
and functionally distinguished from its previously defined apoptosis
inhibition activity, which thenprovidesa generalbasis for evaluating
their functional contributions in vivo during viral infections.
vBcl-2 Da1 and DBH2 Mutants Have No Effect on cHV68
Lytic Replication in vitro and in vivo
To determine the role of the vBcl-2-mediated inhibition of
autophagy and apoptosis during viral infection, we first examined
the in vitro growth properties of the recombinant cHV68 viruses
expressing HA-tagged WT and the mutant forms of vBcl-2 in
comparison to WT cHV68 in both BHK21 cells and NIH3T3
cells (Figure 6A and S4). The cHV68 vBcl-2Da1a n dDBH2
mutant viruses, as well as the vBcl-2AAA mutant, grew with the
same kinetics as WT cHV68 in cultured cells (Figure 6A and S4),
suggesting that the vBcl-2-mediated inhibition of autophagy and
Figure 5. Anti-apoptotic Activities of the vBcl-2 Mutant Proteins. NIH3T3 cells stably expressing the WT or mutant forms of vBcl-2 were
treated with TNFa and cycloheximide (CHX) for 12 h, then assayed for cell viability by trypan blue exclusion assay (A), or for apoptosis by TUNEL
staining (B) or for the caspase 3 activation using flow cytometry (C). Apoptotic cells in (B) were counted under high power magnification
(606magnification). Mock, untreated condition. Data represents mean6SEM of combined results from three independent experiments. Scale bars,
100 mm (A), 5 mm (B). **, P,0.0001 versus vector cells.
doi:10.1371/journal.ppat.1000609.g005
Table 1. Summary of the Anti-autophagic and Anti-apoptotic
Activities of vBcl-2 mutants.
Beclin1 Bak Anti-Autophagy Anti-Apoptosis
WT ++ + +
Da1 2 + 2 +
AAA 22 2 2
DBH2 + 2 + 2
DTM ++ + +
doi:10.1371/journal.ppat.1000609.t001
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consistent with the previous reports that cHV68 does not require
vBcl-2 to replicate in vitro [25,27,37]. In accord with their growth
in vitro in fibroblast cells, vBcl-2 mutant cHV68 viruses replicated
at levels comparable to WT cHV68 in the lungs of intranasally
infected BALB/c mice 5 or 7 days postinfection (dpi), as measured
by plaque assay (Figure 6B, left panel) and real-time PCR
(Figure 6B, right panel). No statistically significant differences were
detected among cHV68 WT, the cHV68 mutant lacking vBcl-2
(vBcl-2-null), and the cHV68 recombinants expressing HA-tagged
WT or mutant derivatives of vBcl-2 (Figure 6B). Independent
isolates of cHV68 containing the Da1o rt h eDBH2 mutations of
vBcl-2 replicated normally in the lungs, arguing against the
possibility of chance mutations having occurred elsewhere in the
recombinant virus genomes (Figure S5A). These data collectively
support a dispensable role for vBcl-2-mediated anti-autophagy
and anti-apoptosis in viral lytic replication both in vitro and in
vivo.
Figure 6. In Vitro and In Vivo Lytic Replication of the WT and Recombinant cHV68 Viruses. (A) Single-step (right) and multiple-step (left)
growth curves of the WT and recombinant cHV68 viruses in BHK21 cells. (B) Acute replication of the WT and mutant vBcl-2 cHV68 viruses in the lungs
of BALB/c mice at 5 dpi (up) and 7 dpi (down) after intranasal infection determined by viral titers in the lungs of the infected mice (left) or by real-
time PCR of the viral genomic DNA (right). Mean6SEM of five mice per group/experiment. Data of 7 dpi is pooled from two separate experiments.
The vBcl-2 Da1 and DBH2 mutants did not yield significantly different results when compared to the WT in infectious virus titers [for Da1, P=0.82
(day 5); P=0.08 (day 7); for DBH2, P=0.49 (day 5); P=0.54 (day 7); unpaired t-tests] and in viral genome loads in the lungs [for Da1, P=0.25 (day 5);
P=0.28 (day 7); for DBH2, P=0.21 (day 5); P=0.37 (day 7); unpaired t-tests]. n.s., not significant.
doi:10.1371/journal.ppat.1000609.g006
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Impaired in Maintenance of Latency
After immune clearance of acute replication, cHV68 establishes
latency in splenocytes, macrophages, and dendritic cells
[38,39,40]. Disruption of vBcl-2 has been indicated to abrogate
cHV68 from establishment of latency and/or reactivation [25,27].
To determine which of the two activities of vBcl-2, anti-autophagy
versus anti-apoptosis, might be primarily responsible for vBcl-2
function in vivo, we next evaluated the capacities of the
recombinant cHV68 vBcl-2 mutant to confer chronic infection
in mice in comparison to that of WT cHV68. BALB/c mice were
intranasally infected with 5,000 PFU of cHV68 WT or mutants.
By 12 and 14 days after infection, when WT cHV68 had reached
its peak latent load in the spleen, the splenocytes were isolated and
the viral latent loads were assessed by an infectious center assay as
previously described [41]. Virus-driven splenomegalies were found
in all infected mice, but no significant differences in spleen cell
numbers were observable among the samples (data not shown).
The virus titer of the vBcl-2 mutant including vBcl-2Da1, vBcl-
2DBH2, vBcl-2AAA, and vBcl-2 null, was similar to the WT in
BALB/c mice (Figure 7A and 7B, left). Consistent with the
infectious center data, the vBcl-2 mutant viruses showed peak
levels of viral DNA loads comparable to the WT cHV68 at 12 and
14 dpi, suggesting the normal amplification of latent viruses in the
spleen (Figure 7A right, 7B right). Similar observations could be
made with the independently derived Da1 and DBH2 mutant
viruses (Figure S5B). Our results thus indicate that the loss-of-
function mutations of vBcl-2 in autophagy or apoptosis inhibition,
or both, have no appreciable impact on the establishment of viral
latency in spleens, consistent with earlier finding that vBcl-2 is not
required for the establishment of latency by cHV68 [37].
Given the lack of a role for vBcl-2 during early times of latent
infection, we extended our analyses to determine whether vBcl-2-
mediated autophagy and/or apoptosis affect viral maintenance of
splenic latency at later time points. No significant difference in
splenic latency between WT and the vBcl-2 mutant cHV68 was
detected at day 21 (Figure 7C). However, by 28 days postinfection,
the titers of vBcl-2 mutant viruses, including the independently
derived vBcl-2Da1 and vBcl-2DBH2 mutants, were dropped 6- to
10- fold when compared to the WT (P,0.001; Figure 7D up and
S5C). Notably, this defect was not transient, but persisted 35 days
and 42 days postinfection with a substantial, greater than 10-fold
reduction in infectious center titers between WT and the vBcl-2
mutant cHV68, which represents an approximate 90% decrease
in the frequency of latent viruses able to reactivate ex vivo.
(Figure 7E and 7F up). These results indicate that there was a
sustained deficiency of the vBcl-2 mutant viruses in the
maintenance of latency after infection. A contraction of latently
infected splenocytes was apparent at 42 dpi for both the WT and
vBcl-2 mutant viruses (Figure 7F up). In all of the analyzed mice,
preformed infectious viruses were undetectable in equivalent,
freeze-thawed spleen samples (data not shown). Taken together,
these data suggest that although vBcl-2 mutant viruses initially
establish latency at levels equivalent to that of WT, there seems to
be a steady decline of the latent virus reservoir at later time points
in mice infected with the virus lacking a functional vBcl-2.
Since the infectious center assay does not distinguish between
reductions in viral latent loads versus a failure of the latent virus
itself to reactivate, we quantitated the viral genomes per splenocyte
sample by real-time PCR to further measure the degree of viral
latency. In agreement with the reduced infectious center titers at
later time points, the viral genome load of the vBcl-2Da1 mutant
virus was severely reduced compared to that of WT viruses over
the day 28 to day 42 time course in repeated experiments
(Figure 7D, 7E, and 7F down, and S5D). In fact, the cHV68 vBcl-
2Da1 mutant, which expresses an anti-autophagy defective vBcl-2,
was nearly as impaired as the AAA and vBcl-2-null mutant viruses
(Fig. 7D, 7E, 7F down). The close correlation between viral
genome loads and the frequency of latent cHV68vBcl-2Da1
reactivation ex vivo at later times postinfection substantiates a
severe latency defect of the cHV68 vBcl-2Da1 virus. Since
deletion of the a1 helix abolished vBcl-2’s anti-autophagic activity
but retained its anti-apoptotic function, the impaired latency
associated with the vBcl-2Da1 mutant virus infection at later times
thus suggests that autophagy evasion by vBcl-2 plays an important
role in maintaining cHV68 latent infection in splenocytes, whereas
vBcl-2-mediated anti-apoptosis may not be absolutely required or
sufficient for maintaining cHV68 latency. Indeed, the vBcl-
2DBH2 mutant defective for apoptosis inhibition yet retaining
Beclin1-binding and autophagy inhibition intact maintained viral
genome loads equivalent to WT virus (Figure 7D, 7E, 7F down
and S5D), arguing that the DBH2 mutation had no significant
impact on viral latency. Yet, in marked contrast to the normal
viral genome loads and splenocyte numbers (Figure S5E) in the
DBH2 mutant virus-infected mice, the infectious center titer of the
vBcl-2DBH2 mutant was significantly lower than WT cHV68 at
later times, as previously described (Figure 7D, 7E, and 7F up).
The disparity between the viral genome load and the latent viral
titer argues that although the cHV68 vBcl-2DBH2 mutant virus is
capable of maintaining a WT-level viral DNA load, it is unable to
efficiently reactivate from latency in the spleen between day 28
and day 42 after infection. Since the BH2 domain is involved in
the ability of vBcl-2 to inhibit apoptosis but not autophagy, this
result thus suggests that the inhibition of host apoptosis by vBcl-2 is
required for efficient ex vivo reactivation from the latent state
particularly at later time points after infection, which is consistent
with the previous report that the cHV68 vBcl-2 is required for
latency reactivation [37].
The viral capacity of latency maintenance is prerequisite for
establishing lifelong persistent infection of cHV and is often
associated with various malignancies. Our study of the vBcl-2
mutant cHV68 viruses thus indicates that vBcl-2-mediated anti-
autophagy and anti-apoptosis may play distinct role in cHV68
persistent infection, in that autophagy evasion by vBcl-2 is
particularly required for the maintenance of viral latency, while
the vBcl-2-mediated inhibition of apoptosis may play a role during
upon viral reactivation.
Discussion
Here we provide evidence that the vBcl-2-mediated Beclin1
binding and autophagy inhibition is necessary for the maintenance
of cHV68 latent infection, whereas the capability of vBcl-2 to
antagonize the host apoptosis response is required for efficient viral
reactivation from latency ex vivo. Our study thus for the first time
indicates that the vBcl-2-elicited anti-autophagy and anti-apoptosis
activities are functionally and genetically distinct, also suggesting
that the evasion of autophagy represents a critical step in the
lifecycle and/or pathogenesis of cHVs.
The anti-apoptotic Bcl-2 proteins are structurally characterized
by a hydrophobic surface groove that can accommodate the BH3
domain of the pro-apoptotic Bcl-2 family members as well as the
BH3-like domain of Beclin1. Structural alignments of the BH3-like
domain of Beclin1 and the BH3 domain of the pro-apoptotic Bcl-2
proteins revealed highly conserved topology and groove contact
sites despite overall sequence variability, leading to the conclusion
that Beclin1 is a putative BH3-only protein [15,18,19]. However,
no apparent apoptosis induction activity has been found with
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that despite their structural overlap, Beclin1 and pro-apoptotic
Bcl-2 proteins interact with vBcl-2 through two discrete modes of
binding that are dependent on a distinct region of vBcl-2. We show
that removing the BH2 domain from vBcl-2 does not affect vBcl-
2’s capacity to bind and suppress Beclin1, but it significantly
dampens its anti-apoptotic activity. By contrast, deleting the a1
helix does not affect vBcl-2’s capacity to suppress apoptosis, yet
strikingly impairs its anti-autophagic activity. We thus propose that
the anti-apoptotic function of vBcl-2 is not required for its effect on
autophagy inhibition and vice versa. Compared to a previous
study of the vBcl-2-Beclin1 interaction in vitro [19], our in vivo
data further demonstrates that mutations of vBcl-2 outside the
vBcl-2-Beclin1 BH3 domain interface (e.g. vBcl-2Da1) also affect
vBcl-2-Beclin1 binding affinity, probably by altering the confor-
mation of the hydrophobic cleft composed of the BH1, BH2, and
BH3 domains. It can be speculated that not only do different BH3
domains have distinct binding footprints on the vBcl-2 surface
groove as previously described [19], but that vBcl-2 undergoes
different conformational changes when bound to distinct BH3
domain sequences. Thus, our data, in conjunction with recent
findings [19,28], provides a molecular explanation for the
distinctly different roles of vBcl-2-mediated apoptosis and
autophagy regulation in living cells.
cHV68 vBcl-2 is required for persistent viral replication and
reactivation of the virus from latency [25,27,37]; two types of
biological activities have been described: anti-apoptosis and anti-
autophagy. However, it has not been possible to experimentally
delineate their relative contributions to overall vBcl-2 functions in
vivo. Our studies have allowed us to genetically distinguish the role
of vBcl-2-mediated blockage of autophagy in vivo from vBcl-2-
mediated anti-apoptosis by constructing a recombinant mutant
virus that has the ability to block apoptosis but is unable to inhibit
autophagy in infected cells. This mutant virus is highly attenuated
in maintaining viral latency, suggesting that the vBcl-2-mediated
inhibition of host-cell apoptosis is not sufficient to confer persistent
infection, but rather that the vBcl-2-mediated blockage of Beclin1-
dependent autophagy is required for the efficient maintenance of
viral latency, a prerequisite for subsequent reactivation and
transmission. This finding seems to be without precedent because
vBcl-2 homologs have not been recognized to directly contribute
to viral latent infection by interfering with the host autophagy
machinery. Our data, however, do not rule out an important role
for apoptosis, likely provided by other viral factors, in maintaining
viral latency in vivo but, instead, they identify a vBcl-2-associated
autophagy defect in chronic infection of cHV68. Analogous to
cHV68 vBcl-2, KSHV-encoded vBcl-2 has been found to target
Beclin1-dependent autophagy more strongly than cellular Bcl-2
[12,30]. Given their poor overall amino acid homology to cellular
Bcl-2 family members, the conservation of a mechanism of
autophagy inhibition strongly supports the notion that interfering
with the host autophagic machinery likely represents a common
strategy for latent infection shared by these, and possibly other
persistent cHVs. Nonetheless, it remains possible that the impaired
latency that we observed with the vBcl-2 mutant cHV68 virus is
not simply due to the disabled anti-autophagic activity of vBcl-2
but other as-of-yet undefined mechanisms. Future studies of viral
replication and pathogenesis in mice lacking functional autophagy
genes should help address this contingency.
Notably, two previous studies have also demonstrated the
functional role of vBcl-2 during cHV68 chronic infection but
with slightly different results [37]. In contrast to our findings that
vBcl-2 is required for efficient maintenance of cHV68 latency,
Gangappa et al. did not observe evident defects in the splenic
latency of the vBcl-2 mutant [37]. As previously noted [27,42],
this discrepancy is potentially due to the use of different viral
administration routes: intraperitoneal inoculation in Gangappa
et al. versus intranasal inoculation in our study. On the other
hand, de Lima et al. observed a reduced efficiency in the initial
establishment of cHV68 splenic latency in the absence of a
functional vBcl-2 as early as day 14 postinfection, which was
subsequently recovered 6 months postinfection [27]. However, in
our study with the vBcl-2 mutant viruses, the latency defect was
not detected until 4,6 weeks postinfection, the period in which a
contraction of latently infected splenocytes was apparently
observed. The basis for the differences between these data and
our findings is not yet clear. It is possible that the higher dose
inoculation (2610
4 PFU) used by de Lima et al might provoke
stronger proinflammatory responses in the lung, which may
presumably affect the initial viral seeding and amplification in the
spleen. Alternatively, the vBcl-2 may carry out additional
activities other than anti-apoptosis and anti-autophagy that
contribute to the chronic infection of cHV68. Despite the
discrepancies revealed in different experimental settings, the lack
of absolute ablation of latency upon infection with the cHV68
vBcl-2 mutant suggests a complex nature of cHV68 persistence,
involving multiple viral factors and cellular processes. Neverthe-
less, our studies on the role of vBcl-2, particularly its anti-
autophagy function, in the maintenance of splenic latency
highlight the importance of autophagy during cHV68 infection.
Despite the fact that vBcl-2 is primarily expressed during the
cHV68 lytic cycle and that it efficiently blocks apoptosis in cell
culture and in transgenic models [25,26,37], cHV68 vBcl-2 is
dispensable for the initial evasion of apoptosis in acute infections,
as also shown by Gangappa et al. and de Lima et al. [27,37]. In this
respect, one would expect that other anti-apoptotic lytic cHV68
Figure 7. Distinct Roles for the vBcl-2-mediated Inhibition of Autophagy and Apoptosis in cHV68 Chronic Infections In Vivo. Splenic
infectious centers measured at 12 dpi (A, left), 14 dpi (B, left), 21 dpi (C, left), 28 dpi (D, up), 35 dpi (E, up), or 42 dpi (F, up) and viral genome load
measured by real-time PCR at 12 dpi (A, right), 14 dpi (B, right), 21 dpi (C, right), 28 dpi (D, down), 35 dpi (E, down), or 42 dpi (F, down), in the BALB/c
mice intranasally infected with the WT or recombinant cHV68 mutants, as indicated (Mean6SEM of five mice per group/time point/experiment). Data
of 14 dpi and 28 dpi is pooled from two and three separate experiments, respectively. Preformed infectious virus was negligible in all spleen samples.
No significant difference was detected at 12 dpi (A), 14 dpi (B), and 21 dpi (C) with the Da1 and DBH2 mutant viruses when compared to the WT in
infectious center titers [for Da1, P=0.58 (day 12); P=0.75 (day 14); P=0.18 (day 21); for DBH2, P=0.64 (day 12); P=0.73 (day 14); P=0.81 (day 21);
unpaired t-tests] and in viral genome loads [for Da1, P=0.85 (day 12); P=0.76 (day 14); P=0.96 (day 21); for DBH2, P=0.56 (day 12); P=0.73 (day 14);
P=0.25 (day 21); unpaired t-tests]. At 28 dpi (D), 35 dpi (E), and 42 dpi (F), the decreased infectious center titers (top) of vBcl-2 mutant viruses, as
compared to WT cHV68, were statistically significant [vBcl-2Da1 versus vBcl-2AAA (42 dpi), P=0.46; vBcl-2Da1 versus WT cHV68 (42 dpi), P=0.08;
unpaired t-tests]. At 28 dpi (D), 35 dpi (E), and 42 dpi (F), the decreased viral DNA loads (bottom) of the vBcl-2Da1, vBcl-2AAA, and vBcl-2 null
mutants, as compared to WT cHV68 and the vBcl-2DBH2 mutant, were statistically significant as follows (unpaired t-tests): at day 28, vBcl-2Da1 versus
WT cHV68, P,0.01; vBcl-2AAA versus WT cHV68, P,0.01; vBcl-2-null versus WT cHV68, P,0.01; vBcl-2Da1 versus vBcl-2DBH2, P,0.001; vBcl-2AAA
versus vBcl-2DBH2, P,0.001; vBcl-2-null versus vBcl-2DBH2, P,0.001; at day 35, vBcl-2Da1 versus WT cHV68, P,0.05; vBcl-2AAA versus WT cHV68,
P,0.05; vBcl-2Da1 versus vBcl-2DBH2, P,0.01; vBcl-2AAA versus vBcl-2DBH2, P,0.05; at day 42, vBcl-2Da1 versus vBcl-2DBH2, P,0.001; vBcl-2AAA
versus vBcl-2DBH2, P,0.001; vBcl-2DBH2 versus WT cHV68, P=0.33. I.C., infectious center. *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.ppat.1000609.g007
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recent work by Feng et al. [43] indicates that cHV68 encodes a
mitochondrion-associated anti-apoptotic protein (vMAP) that
effectively antagonizes apoptosis and is required for the lytic
replication of cHV68 in cell culture. It will then be of interest to
test whether vMAP can also antagonize the host autophagy
response and whether autophagy is involved in acute infections of
cHV68. On the other hand, the preferential roles of vBcl-2 at the
late stages of latent infection and ex vivo reactivation from latency
strongly imply that its expression likely continues through into
latent infection [27,37]. This view is strengthened by the detection
of the vBcl-2 transcript in latently infected cells and/or tissues,
albeit in low abundance [41,44,45,46]. However, it should be
noted that because the vBcl-2-encoding M11 gene is interposed in
the opposite orientation between the v-cyclin gene and LANA/
ORF73, with its transcript overlapping with ORF73, it remains
possible that the RT-PCR signal for vBcl-2 may correspond to an
ORF73 mRNA encoded on the opposite strand. Due to the
complex nature of transcription across this region, a strand specific
transcript mapping may be necessary for clarifying the expression
profile of vBcl-2 during different phases of viral infection in mice.
While dispensable for lytic replication, vBcl-2 has been
previously indicated to be required for ex vivo reactivation
[25,37]. We further extended this view by showing that the
reactivation efficiency of vBcl-2 correlates with its anti-apoptotic
ability, not anti-autophagic effect. We found that a mutant strain
of cHV68 that is specifically impaired in the apoptosis-inhibitory
activity of vBcl-2, while remaining competent for autophagy
inhibition, exhibited normal levels of splenic latency but inefficient
ex vivo reactivation of the virus from the latently infected cells,
suggesting that apoptosis evasion by vBcl-2 is particularly
important during the reactivation process of the virus from
latency. Notably, this viral phenotype, associated with the DBH2
mutant, was revealed at day 28 dpi but not at earlier time points of
latency. This implies that the viral maintenance of latency
represents a genetically distinct phase of cHVs infection and
involves different viral and/or host factors. In this scenario, it is
more likely that additional apoptosis inhibitors of cHV68 and/or
the host proteins may be required for, or at least directly involved,
for ex vivo reactivation in the early stage of latency, compensating
for the anti-apoptotic effect of vBcl-2. Therefore, our studies do
not preclude the importance of apoptosis regulation for ex vivo
reactivation at the early stage of latency, but rather have identified
a vBcl-2-associated deficit in latency maintenance. Such a deficit
would also presumably reduce the virulence of cHV68. Further-
more, it has been set forth that the poor viability of explanted
murine B cells may conceivably affect the efficiency of ex vivo
reactivation. It is thus possible that the removal of the BH2
domain, which mitigates the anti-apoptotic properties of vBcl-2,
may affect the survival of explanted B cells, thereby indirectly
impacting the efficiency of the ex vivo reactivation of the virus.
However, this possibility did not manifest itself in the early time
points of viral latency, suggesting that survival of latently infected
B cells in culture does not play a critical role in dictating the
phenotype of the cHV68 vBcl-2 DBH2 mutant and that the vBcl-
2-mediated inhibition of host apoptosis may be more directly
involved in the reactivation programming of cHV68. Neverthe-
less, our study of the requirement of vBcl-2 for both latency
maintenance and reactivation process is consistent with vBcl-2
being expressed in latently infected tissues [45]. It also points to the
unique protective activities of vBcl-2 mutants in apoptosis and
autophagy with respect to distinct phases of viral infection, and
also their coordinated effects on cHV68 persistency and/or
pathogenesis.
cHVs have developed a unique mode of interaction with the
host where they establish lifelong latency and may be reactivated
throughout the life of the host, which has been associated with the
onset of various malignancies. Although it remains to be fully
understood what factors govern the establishment and mainte-
nance of latency, our study clearly demonstrates that sustained
cHV68 latency in splenocytes requires the vBcl-2-mediated
inhibition of the host autophagy machinery. But, how autophagy
functions and what accounts for its effect are not yet understood.
Given the substantial contributions of autophagy to the quality
control of cytoplasmic components in host cell, most simply,
autophagy induction may promote the degradation of cytosolic
viral protein(s) essential for the maintenance of latency. Alterna-
tively, the ‘autophagic digestion’ of viral latent antigens may
facilitate its MHC class II presentation and cytotoxic T cells (CTL)
recognition, as recently exemplified by the nuclear antigen 1 of
Epstein-Barr virus (EBNA1) [47]. Additionally, autophagy may
help to deliver a ‘viral signal’ to TLR-containing endosomes, thus
stimulating the IFNa production that has been proven to be
important to the control of acute cHV68 infection as well as
latency [48,49,50,51]. It is also possible that the autophagy
induced when Beclin1 is unchecked by vBcl-2 can trigger cell
death of latently infected cells, such a scenario is supported by the
fact that a Beclin1 mutant unable to bind to Bcl-2 induces caspase-
independent autophagic cell death [12]. The observations that
autophagy may promote the sequestration and digestion of
replicating viruses inside the host cell as described in HSV-1
[52,53] could also provide an attractive explanation for the
restriction of persistent infection of cHV68, but direct evidence is
missing. While it is not yet clear by which mechanism(s) autophagy
restricts viral persistency, none of these mechanisms are mutually
exclusive and there may be other consequences of autophagy
function relating to the activation of the host immune responses
against cHV68 and latency, as well. Further studies examining the
molecular details involved in the vBcl-2-mediated inhibition of
autophagy will expand our understanding of both autophagy and
cHV-associated pathogenesis and reveal novel targets for antiviral
therapy.
In conclusion, we have described a crucial role for the viral
evasion of autophagy in latent viral infections. Beyond its
established anti-apoptotic functions, vBcl-2 targets the host
autophagy effector protein Beclin1 and this activity of vBcl-2 is
essential to the viral maintenance of latency. Our findings thus
indicate that two host innate immune pathways, autophagy and
apoptosis, both targeted by vBcl-2, actually conduct hitherto
unexpected and distinctive roles in protecting against viral
infections. Future studies will aim to analyze in detail the
molecular mechanisms of autophagy that contributes to control-
ling cHV infection.
Materials and Methods
Mice
All mice handling was performed in accordance with the
Animal Research Committee guidelines of the University of
Southern California (USC) and the University of California, Los
Angeles. All methods used herein have also been approved by the
USC Animal Research Committee. BALB/c mice were obtained
from Charles River Laboratories, Inc. (Wilmington, MA). All mice
(,6-week old, n=5,8 per pool) were infected intranasally with
5,000 plaque-forming units (PFU) of cHV68 viruses under brief
halothane anesthesia and the infected mice were sacrificed at 5
and 7 days post-infection (dpi) to measure acute infection in the
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measure viral latent load in the spleen.
Cell culture and viruses
NIH3T3, BHK21 and 293T cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, and 1% penicillin-streptomycin
(Gibco-BRL). Transient transfection was performed with Fugene 6
(Roche), Lipofectanine 2000 (Invitrogen), or Calcium phosphate
(Clontech). NIH3T3 stable cell lines were established using a
standard protocol of selection with 2 mg/ml of puromycin (Sigma-
Aldrich). The wild-type (WT) cHV68 virus, pBAC/cHV68 virus
[54], and its mutant derivatives were all propagated in BHK21
cells for in vitro studies and in NIH3T12 cells for in vivo studies.
Plasmid construction
A DNA fragment corresponding to the cHV68 vBcl-2 coding
sequence was amplified from S11 genomic DNA. The PCR-
amplified vBcl-2 DNA was then cloned into a modified pEF-
IRES-puro vector (Invitrogen) encoding an N-terminal HA tag
(pEF-HA-vBcl-2). Mutations in the vBcl-2 gene were generated by
PCR (Hi-Fidelity PCR kit, Roche) with oligonucleotide-directed
mutagenesis. Specifically, vBcl-2 Da1 (lacking the N-terminal 21
residues) and DTM (lacking the C-terminal 20 residues) deletion
constructs were amplified from the pEF-HA-vBcl-2 vector using
specific primers; The vBcl-2 DBH2 (lacking residues 129-144 of
BH2 domain) and Da7 [lacking residues 130–134 (NHFPL)]
mutants were created via two-step PCR mutagenesis. The HA-
vBcl-2 AAA mutant with alanine substitutions at the Ser85-Gly86-
Arg87 residues was created using a Quickchange site-directed
mutagenesis kit (Stratagene). All of the PCR products with the
indicated vBcl-2 mutations were then cloned in frame into the
XhoI/MluI sites of the pEF-IRES-puro vector, for both transient
and stable expression. All mutant constructs were completely
sequenced to ensure the presence of the desired mutation and the
absence of secondary mutations. Constructs expressing the HA-
tagged Bcl-2 family proteins were kindly provided by J. Marie
Hardwick (John Hopkins university). The Beclin1-V5 plasmid has
been described previously [29]. For yeast-two hybrid analyses,
vBcl-2 and its mutant derivatives were cloned into the EcoRI/
BamHI sites of the yeast plasmid pGBKT7 (Clontech), which
carries the S. cerevisiae TRP1 gene as a selectable marker. The BH3-
like domain (residues 88-150) of Beclin1 was subcloned into the
EcoRI/XhoI sites of the pGADT7 vector (Clontech), harboring the
LEU selection marker. To produce a GST fusion protein of Bak
(GST-BakDTM) from E. coli, the PCR product of Bak cDNA with
a deletion of the C-terminal TM region was subcloned into the
EcoRI/XhoI sites of pGEX4T-1. All constructs were sequenced
using an ABI PRISM 377 automatic DNA sequencer.
Viral mutagenesis
To make specific mutants of cHV68 (i.e. HA-WT, HA-Da1,
HA-DBH2, and HA-AAA), the two-step bacteriophage lambda
Red-mediated homologous recombination method was performed
using the cHV68 bacterial artificial chromosome (BAC) clone in
GS1783 (an E. coli strain containing an arabinose-inducible I-SceI
gene, provided by G. Smith, Northwestern University Medical
School) as previously described [55]. Briefly, PCR was used to
generate constructs containing the kanamycin-resistance (Kan
R)
gene with the mutated vBcl-2 gene. This kanamycin cassette was
then inserted into the cHV68 BAC clone by homologous
recombination and a markerless mutation was achieved through
the deletion of the kanamycin resistance gene using I-SceI.
Consequent mutations in the BAC DNAs were confirmed by
DNA sequencing and the genomic integrity of the mutated BAC
MHV-68 was investigated by restriction enzyme digestion and
southern blot analysis as previously described [54]. vBcl-2-null
BAC was generated by the in vitro MuA transposition of signature
tagged transposon [54]. All BACs were reconstituted into
infectious viruses by transfecting the BAC DNA along with the
Cre recombinase-expressing plasmid, which removes BAC vector
sequence, into NIH3T12 cells using Lipofectamine Plus reagent
(Invitrogen). The produced viruses were purified as single clone by
limiting dilution and then amplified in NIH3T12 cells. The
purified viral stock was tittered by plaque assays, using a
monolayer of Vero cells overlaid with 1% methylcellulose. By 5
days post-infection, the cells were fixed and stained with 2%
crystal violet in 20% ethanol. Plaques were then counted to
determine infectious titer.
Yeast two-hybrid assay
To analyze the interactions between the Beclin1 and vBcl-2
mutants, yeast strain AH109, expressing the BH3-like domain of
Beclin1 fused to the Gal4 activation domain in the pGADT7
plasmid, was used to transform pGBKT7 plasmids containing the
mutants of vBcl-2, and the transformants then assayed for a-
galactosidase activity, as previously described [56].
Autophagy analyses
Quantitative GFP-LC3 light microscopy autophagy assays were
performed in NIH3T3 stable cells expressing the WT or mutant
forms of vBcl-2, then transfected with a GFP-LC3-expressing
plasmid [35]. Autophagy was then induced by starvation or
rapamycin treatment. For starvation, the cells were washed three
times with PBS and incubated in Hank’s solution (Invitrogen) for
4 h at 37uC. Alternatively, the cells were cultured in DMEM
containing 1% FBS and 2 mM rapamycin (Sigma-Aldrich) for 6 h.
LC3 mobility shift was detected by immunoblotting as previously
described [29]. For autophagy levels during viral infection,
NIH3T3 cells were transfected with GFP-LC3, then infected with
recombinant cHV68 WT or mutant viruses at an MOI of 5, and
fixed 18 h after infection.
Apoptosis analyses
NIH3T3 cells stably expressing the WT or mutant forms of
vBcl-2 were seeded at 1610
6 cells per well into 6-well plates for
24 h. The cells were then treated with fresh medium containing
2 ng/ml tumor necrosis factor alpha (TNFa) plus 1 mg/ml
cycloheximide (CHX) for up to 12 h. For the cell viability assay,
the cells were stained with trypan blue for dye exclusion. For the
analysis of apoptotic cells, the samples were prepared using an
DEADEND
TM Fluorometric TUNEL system kit (Promega) ac-
cording to the manufacturer’s instructions. Nuclei were counter-
stained with 4, 6-diamidino-2-phenylindole (DAPI). Fluorescence
microscopy analyses were performed with an Olympus IX-70
microscope. The percentage of TUNEL-positive cells was
determined against the number of DAPI-stained nuclei. For the
PI staining assay, the cells were collected with the cell dissociation
buffer (Sigma-Aldrich) and then fixed with 70% of ethanol
overnight at 220uC. Fixed cells were washed twice with PBS, and
incubated in PBS containing propidium (PI; 5 mg/ml), RNase A
(1 mg/ml), and Triton X-100 (0.5%) at room temperature for
30 min. Fluorescence emitted from the propidium–DNA complex
was measured using FACScan flow cytometry. Cells containing
hypodiploid DNA were considered apoptotic. The data was
analyzed using Cell Quest (BD Bioscience). For caspase-3 activity
assay, the cells were harvested after treatment, washed three times
with PBS and fixed with fixation medium (Invitrogen, Catalog#
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Medium (Invitrogen, Catalog# GAS002S) for another 15 min,
and then stained with PE-conjugated anti-Caspase3 active form
(BD biosciences #550821) for flow cytometry analysis. Data was
analyzed by FlowJo-6.4. For apoptotic levels during viral infection,
NIH3T3 cells were infected with recombinant cHV68 WT or
mutant viruses at an MOI of 5, and apoptosis was assessed by
TUNEL staining and nuclei counterstaining as described above.
Growth curves
BHK21 cells and NIH3T3 cells were seeded at 2610
5 cells per
well into 6-well plates for the single-step growth curve with a
multiplicity of infection (MOI) of 5.0, or at 1610
5 cells per well for
multi-step growth curves with an MOI of 0.1. The samples were
harvested at various time points post-infection, subjected to three
freeze-thaw cycles, then titered by plaque assay in triplicate as
previously described [37].
Lung titer and infectious center assay
To determine the virus titer in the infected lungs, the lungs were
homogenized in 1 ml of DMEM and the infectious viruses in the
homogenate supernatants was measured by three independent
plaque assays. For infectious center assay, which measures the
amount of the latent virus that is able to reactivate from the
latently infected B cells, single cell suspensions of splenocytes were
prepared from the infected spleens and co-cultivated with a
monolayer of Vero cells overlaid with 1% methylcellulose. The
Vero cells were incubated further for 5 days, then fixed and
stained with 2% crystal violet in 20% ethanol. Plaques were then
counted to determine the infectious centers [57]. A majority of the
samples in the assay for preformed viruses resulted in no plaque,
with a minority of samples displaying 1 to 2 plaques per ,10
7
splenocytes.
Quantification of the viral genome
For quantification of viral genome load from the infected cells/
tissues, total genomic DNA from the infected organs was prepared
and subjected to quantitative real-time PCR, as previously
described [54]. Briefly, total genomic DNA from the infected
lungs or the spleen tissues was extracted using a DNeasy Tissue Kit
(QIAGEN, Valenia, Calif.), according to manufacturer’s instruc-
tions. cHV68 ORF56-specific primers (forward primer: 59-
GTAACTCGAGACTGAAACCTCGCAGAGGTCC-39; re-
verse primer: 59-CCGAAGCTTGCACGGTGCAATGTGTCA-
CAG-39) were used in the assay. The DNA templates were mixed
with 26Master mix (Biorad iQ
TM SYBRH Green Supermix) and
PCR was performed at 95uC for 159 and 45 cycles of 95uC for 300,
60uC for 300, and 72uC for 300, followed by melting curve
analyses. 100–500 ng of DNA was analyzed in duplicate for each
sample and compared with a standard curve of a BAC plasmid
containing the cHV68 genome, serially diluted with uninfected
cellular DNAs and amplified in parallel. Amplification and
detection were performed using Opticon II (MJ Research). The
specificity of the amplified products was confirmed by agarose gel
electrophoresis.
Quantitative analyses of v-cyclin transcript were performed
using SYBR GreenER
TM qPCR Kit (Qiagen) on a DNA Engine
OpticonH 2 continuous Fluorescence Detection System (MJ
Research, Incorporated, Waltham, MA). Total RNA was
extracted from the infected cells using Trizol (Invitrogen) and
100 ng of purified total RNA was reverse transcribed to cDNA
using a cDNA synthesis kit (Invitrogen). The PCR reaction was set
according to the manufacturer’s recommendations. Briefly, after
an initial 5 minutes of denaturation at 95uC, thermal cycling was
performed at 94uC for 450,5 7 uC for 19, and 72uC for 19 for a total
of 40 cycles followed by a melting curve analyses. The amount of
RNA was normalized with the quantified b-Actin in each sample.
The primer sets for amplification of orf72 were: forward, 59-
GGAGCAACAACAGCTGACAA-39; reverse, 59-GTGATTAG-
CACTGGGCGTTT-39. The primer sets for b-Actin were:
forward, 59-CGAGGCCCAGAGCAAGAGAG-39; reverse, 59-
CGGTTGGCCTTAGGGTTCAG-39. Quantitative experiments
were performed at least three times, including a no-template
control each time. The size of the amplified products was
confirmed by agarose gel electrophoresis.
Immunoblotting, immunoprecipitation and GST pull-
down
For immunoblotting, the polypeptides were resolved by SDS-
PAGE and transferred onto a PVDF membrane (Bio-Rad). The
membranes were blocked with 5% non-fat milk, and probed with
the indicated antibodies. Goat antibodies coupled to horseradish
peroxidase specific to mouse or rabbit immunoglobulins were used
as secondary antibodies (diluted 1:10,000, Sigma-Aldrich). Im-
munodetection was achieved with a chemiluminescence reagent
(Pierce) and detected by a Fuji Phosphor Imager (BAS-1500; Fuji
Film Co., Tokyo, Japan).
For immunoprecipitation, cells were harvested and then lysed in a
1%NP40 lysis buffer supplementedwith completeprotease inhibitor
cocktail (Roche). After pre-clearing with protein A/G agarose beads
for 1 h at 4uC, whole-cell lysates were used for immunoprecipitation
with the indicated antibodies. Generally, 1–4 mg of the commercial
antibodies was added to 1 ml of the cell lysate, which was then
incubated at 4uC for 8–12 h. After addition of protein A/G agarose
beads, incubation was continued for another 2 h. Immunoprecip-
itates were extensively washed with an NP40 lysis buffer and eluted
with an SDS-PAGE loading buffer by boiling for 5 min.
For in vitro GST pull-down assay, GST by itself or a GST-
BakDTM fusion protein was purified from E.coli strain BL21 (DE3)
(Promega). 293T cell lysates were incubated with glutathione
beads containing the GST fusion protein in a binding buffer
(20 mM HEPES [pH 7.4], 100 mM NaCl, 1% NP-40, and
protease inhibitors) for 2 h at 4uC. The glutathione beads were
then washed four times with the binding buffer, and the proteins
associated with the beads were analyzed by SDS-PAGE and
subjected to immunoblot assay with the phosphorimager.
Immunofluorescence and confocal laser scanning
microscopy
NIH3T3 stable cells grown on 8-well chamber slides were fixed
with 2% (w/v) paraformaldehyde in PBS for 20 min, permeabi-
lised with 0.2% (v/v) Triton X-100 for 15 min and blocked with
10% goat serum (Gibco-BRL) for 1 h. Primary antibody staining
was performed using antiserum or purified antibodies in 1% goat
serum for 1–2 h at room temperature. The cells were then
extensively washed with PBS and incubated with diluted
secondary antibodies in 1% goat serum for 1 h. The cells were
mounted using Vectashield (Vector Laboratories, Inc.). The
confocal images were acquired using a Leica TCS SP laser-
scanning microscope (Leica Microsystems, PA) fitted with a 1006
Leica objective (PL APO, 1.4NA) and Leica image software.
Statistical analysis
Statistical analyses were performed using unpaired t-tests.
Values are expressed as mean6SEM of at least three independent
experiments unless otherwise noted. A P value of #0.05 was
considered statistically significant.
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Figure S1 (A) NIH3T3 cells stably expressing WT or mutant
forms of vBcl-2 were transfected with GFP-LC3, then incubated
under normal or starvationconditions for 4 h.The number of GFP-
LC3-positive dots per cell was counted using a fluorescence
microscope. Data represents mean6SEM of the combined results
from three independent experiments. **, P,0.0001. (B) The
expression of WT and mutant vBcl-2 proteins in NIH3T3 cells
was determined by immunoblotting using an anti-HA antibody.
b-actin was probed as a loading control. (C) Intracellular
localization of vBcl-2 WT and its mutants in NIH3T3 cells.
NIH3T3 cells stably expressing HA-tagged WT vBcl-2 and its
mutants were fixed and the localization of vBcl-2 proteins was
determined by staining with an anti-HA antibody using confocal
microscopy. Scale bar, 5 mm. (D) Restriction enzyme digestion
patterns (top) and Southern blot analysis (bottom) of wild-type (wt)
cHV68 and vBcl-2 mutants. Bacterial artificial chromosome (BAC)
DNAs of wt and mutants were prepared and digested with BamHI,
EcoRI, or HindIII. The digested DNAs were resolved by 1% agarose
gel electrophoresis. M: 1 Kb DNA Ladder (Invitrogen); WT: wild-
type cHV68; Null: vBcl-2 null mutant by transpon-insertion. The
asterisk (*) indicates the heterogeneity of the 40-bp repeat in the
vBcl-2AAA mutant, which often occurs in our BAC system but does
not affect viral replication both in vitro and in vivo [57]. The
enzyme digested DNAs were transferred to nitrocellulose mem-
brane and hybridized with
32P-labeled probes for M11 gene and
transposon. Expected sizes (bp) for BamHI digests: wt cHV68,
5249 bp; null mutant, 3473, 2060, and 1033 bp; HA-WT cHV68,
5288 kb; HA-vBcl-2AAA mutant, 5288 bp; HA-vBcl-2Da1m u -
tant, 5228 bp; HA-vBcl-2DBH2 mutant, 5240 bp. Expected sizes
(bp) for EcoRI digests: wt cHV68, 5186 bp and 3147 bp; null
mutant, 4881, 3147, and 1622 bp; HA-WT cHV68, 5225 bp and
3147 bp; HA-vBcl-2AAA mutant, 5225 bp and 3147 bp; HA-vBcl-
2Da1 mutant, 5165 bp and 3147 bp; HA-vBcl-2DBH2 mutant,
5177 bp and 3147 bp. Expected sizes (bp) for HindIII digests: wt
cHV68, 8357 bp and 2882 bp; null mutant, 8401, 2882, and
1273 bp; HA-WT cHV68, 8396 bp and 2882 bp; HA-vBcl-2AAA
mutant, 8396 bp and 2882 bp; HA-vBcl-2Da1 mutant, 8336 bp
and 2882 bp; HA-vBcl-2DBH2 mutant, 8348 bp and 2882 bp. The
3147 bp and 2882 bp bands for the EcoRI and HindIII digests are
derived from the fragment of the BAC vector that hybridizes to the
probe for M11 gene, because the probe was generated by the
random hexamer labeling of a plasmid containing vBcl-2 gene.
Found at: doi:10.1371/journal.ppat.1000609.s001 (5.19 MB TIF)
Figure S2 (A) Immunoblot analysis of vBcl-2 expression in
NIH3T3 cells infected with the WT cHV68 virus (lane 1),
recombinant cHV68 expressing HA-tagged WT vBcl-2 (lane 2),
Da1 (lane 3), AAA (lane 4), or DBH2 (lane 5) mutants. b-actin was
probed as a loading control. (B) Transcription of v-cyclin in
recombinant cHV68-infected cells in culture. NIH3T3 cells were
infected with the WT or recombinant cHV68 viruses expressing
the indicated vBcl-2 constructs. Total RNA was extracted from the
infected cells and the b-actin normalized v-cyclin expression was
quantified by real-time RT-PCR (bottom) with products of the
reaction electrophoresed in a 2% agarose gel (top). Negative
control (negative ct) indicates reaction from the mock-infected
NIH3T3 cells. Samples were run in triplicate and the data are
representative of three independent experiments.
Found at: doi:10.1371/journal.ppat.1000609.s002 (4.43 MB TIF)
Figure S3 Anti-apoptotic Activities of the vBcl-2 Mutant
Proteins. NIH3T3 cells stably expressing the WT or mutant forms
of vBcl-2 were treated with TNFa and cycloheximide (CHX) for
12 h, then assayed for PI staining followed by flow cytometry
analysis. Apoptosis was quantified as mean6SEM of the combined
results from three independent experiments. PI, propidium iodide.
Found at: doi:10.1371/journal.ppat.1000609.s003 (2.30 MB TIF)
Figure S4 Single-step (bottom) and multiple-step (up) growth
curves of WT and recombinant cHV68 viruses in NIH3T3 cells.
Found at: doi:10.1371/journal.ppat.1000609.s004 (2.02 MB TIF)
Figure S5 (A, B, C, D) BALB/c mice were infected intranasally
with the WT virus, an independent isolate of the Da1( Da1-IND)
mutant, or of the DBH2 (DBH2-IND) mutant cHV68. Viral
genome loads were then measured by real-time PCR at 7 dpi (A)
in the lungs, at 14 dpi (B) and 28 dpi (D) in the spleens. Splenic
infectious centers (C) were also measured at 28 dpi in the spleens.
Values are mean6SEM. n.s., not significant. *, P,0.05; **,
P,0.01; ***, P,0.001. (E) The number of splenocytes of the WT
or mutant vBcl-2 cHV68 infected mice at 28 dpi.
Found at: doi:10.1371/journal.ppat.1000609.s005 (4.95 MB TIF)
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